Changing what’s possible
for people living with T cell-driven autoimmune disease
Selective redosable delivery of siRNA to T cells with cell-targeted lipid nanoparticles (ctLNP)
to reduce or modulate the autoreactive T cells that cause tissue and organ damage in T cell–driven autoimmune diseases.
Potent silencing of genes in T cells while sparing the broader immune system
Our T cell-selective ctLNP delivers siRNA to potently modulate T cell function and avoids off-target uptake by other immune cells and clearance organs, such as the liver and spleen.
Leading the next wave of targeted siRNA therapeutics by reaching T cells selectively
Selective access to new cell types is achieved once a decade. Our ctLNP-siRNA technology opens new targets in T cells to create more powerful, specific development candidates to address T cell–driven autoimmune diseases.
Unlocking the full potential of siRNA therapeutics in T cells
Generation Bio aims to lead the future of T cell–targeted therapeutics, seeking to deliver the genetic precision and tunable pharmacology of siRNA to develop more potent, better-tolerated treatments for autoimmune diseases. Our experienced team fuels our groundbreaking science.